Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-18
2011-01-18
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S447000
Reexamination Certificate
active
07872041
ABSTRACT:
The invention relates to the use of rotigotine, its salts and prodrugs, as a medicament for preventing and/or treating Parkinson's plus syndrome.
REFERENCES:
patent: 4542135 (1985-09-01), Kobel et al.
patent: 4564628 (1986-01-01), Horn
patent: 4722933 (1988-02-01), Horn
patent: 4824860 (1989-04-01), Owen
patent: 4847253 (1989-07-01), Buonamici et al.
patent: 4885308 (1989-12-01), Horn
patent: 5071875 (1991-12-01), Horn
patent: 5151446 (1992-09-01), Horn et al.
patent: 5177112 (1993-01-01), Horn
patent: 5234945 (1993-08-01), Belluzzi
patent: 5382596 (1995-01-01), Sleevi et al.
patent: 5456745 (1995-10-01), Roreger et al.
patent: 5486611 (1996-01-01), Lin et al.
patent: 5496843 (1996-03-01), Nagata et al.
patent: 5545755 (1996-08-01), Lin et al.
patent: 5614518 (1997-03-01), Leeson et al.
patent: 5633376 (1997-05-01), Thurkauf et al.
patent: 5681956 (1997-10-01), Thurkauf et al.
patent: 5807570 (1998-09-01), Chen et al.
patent: 5807855 (1998-09-01), Bogeso et al.
patent: 5891461 (1999-04-01), Jona et al.
patent: 6001861 (1999-12-01), Oertel et al.
patent: 6010877 (2000-01-01), Sathe et al.
patent: 6107318 (2000-08-01), Pocchiari et al.
patent: 6221627 (2001-04-01), Sathe et al.
patent: 6227875 (2001-05-01), Wu et al.
patent: 6331636 (2001-12-01), Romero et al.
patent: 6372920 (2002-08-01), Minaskanian et al.
patent: 6884434 (2005-04-01), Muller et al.
patent: 7309497 (2007-12-01), Rimpler et al.
patent: 7413747 (2008-08-01), Mueller et al.
patent: 7632859 (2009-12-01), Li et al.
patent: 2003/0026830 (2003-02-01), Lauterback et al.
patent: 2003/0027793 (2003-02-01), Lautertback et al.
patent: 2003/0166709 (2003-09-01), Rimpler et al.
patent: 2004/0034083 (2004-02-01), Stephenson et al.
patent: 2004/0048779 (2004-03-01), Schollmayer
patent: 2004/0081683 (2004-04-01), Schacht et al.
patent: 2004/0116537 (2004-06-01), Li et al.
patent: 2004/0137045 (2004-07-01), Breitenbach et al.
patent: 2004/0198753 (2004-10-01), Kase et al.
patent: 2004/0209861 (2004-10-01), Benavides et al.
patent: 2005/0032843 (2005-02-01), Pieper et al.
patent: 2005/0033065 (2005-02-01), Mueller et al.
patent: 2005/0079206 (2005-04-01), Schacht et al.
patent: 2005/0175678 (2005-08-01), Breitenbach
patent: 2005/0182090 (2005-08-01), Mierau et al.
patent: 2005/0197385 (2005-09-01), Scheller et al.
patent: 2005/0260254 (2005-11-01), Breitenbach et al.
patent: 2006/0263419 (2006-11-01), Wolff
patent: 2007/0072917 (2007-03-01), Scheller et al.
patent: 2007/0093546 (2007-04-01), Scheller et al.
patent: 2007/0191308 (2007-08-01), Kramer
patent: 2007/0197480 (2007-08-01), Scheller et al.
patent: 2008/0008748 (2008-01-01), Beyreuther et al.
patent: 2008/0138389 (2008-06-01), Muller et al.
patent: 2008/0146622 (2008-06-01), Scheller et al.
patent: 2008/0274061 (2008-11-01), Schollmayer et al.
patent: 2009/0143460 (2009-06-01), Wolff et al.
patent: 2 532 804 (2005-02-01), None
patent: 2 532 859 (2005-02-01), None
patent: 2 547 820 (2005-06-01), None
patent: 2 546 797 (2005-07-01), None
patent: 2 568 850 (2006-02-01), None
patent: 1256339 (2002-11-01), None
patent: WO 93/00313 (1993-01-01), None
patent: WO 94/26703 (1994-11-01), None
patent: WO 96/31210 (1996-10-01), None
patent: WO 97/29735 (1997-08-01), None
patent: WO 99/49852 (1999-10-01), None
patent: WO 00/03715 (2000-01-01), None
patent: WO 00/02053 (2000-06-01), None
patent: WO 00/35954 (2000-06-01), None
patent: WO 00/38669 (2000-07-01), None
patent: WO 01/38321 (2001-05-01), None
patent: WO 01/39756 (2001-06-01), None
patent: WO 01/62249 (2001-08-01), None
patent: WO 02/15903 (2002-02-01), None
patent: WO 02/31499 (2002-04-01), None
patent: WO 02/38646 (2002-05-01), None
patent: WO 02/018382 (2002-07-01), None
patent: WO 02/089777 (2002-11-01), None
patent: WO 02/089778 (2002-11-01), None
patent: WO 03/007803 (2003-01-01), None
patent: WO 03/012137 (2003-02-01), None
patent: WO 03/029233 (2003-04-01), None
patent: WO 03/069332 (2003-08-01), None
patent: WO 03/076658 (2003-09-01), None
patent: WO 03/088958 (2003-10-01), None
patent: WO 2004/012719 (2004-02-01), None
patent: WO 2004/012721 (2004-02-01), None
patent: WO 2004/012730 (2004-02-01), None
patent: WO 2004/050083 (2004-06-01), None
patent: WO 2004/058247 (2004-07-01), None
patent: WO 2005/070428 (2005-08-01), None
patent: WO 2006/050976 (2006-03-01), None
patent: WO 2006/039532 (2006-04-01), None
Dawson (2002) Nature Neuroscience Supplement, vol. 5, 1058-1061.
Den Daas (1990) Naunyn-Schmiedeberg's Archives of Pharmacology 341, 186-191.
Den Daas (1990) Naunyn-Schmiedeberg's 342, 655-659.
Den Daas (1991) J. Pharm. Pharmacology 43, 11-16.
Eberhardt (2003) Toxicology Letter 139(2), 135-151.
Fahn et al. (1987) Recent Developments in Parkinson's Disease vol. 2, pp. 153-163, 293-294.
Gerlach (2003) Neurotox. Res. 5(1), 43-51.
Hirsch (2003) Ann NY Academy Science 991, 214-228.
Hobson (2003) Can. J. Neurol. Sci. 30(Suppl 1) S2-S9.
Lev (2003) Prog. Neuropsychopharm. Biol. Psychiatry 27(2), 245.
Mark (2001) Neurol. Clin. 19(3), 607-627.
Metman (2001) Clinical Neuropharmcology 24(3), 163-169.
Michel et al. (2002) Rev. Neurol. (Paris) 158 Spec No. 1, pp. 7S24-7S32.
Mucke (2003) IDrugs 6(9), 894-899.
Neophytides et al. (1982) J. Neurology Neurosurgery Psychiatry 45, 261-263.
Newman-Tancredit et al. (2002) J. Pharm. And Experimental Ther. 303(2), 805-814.
Parkinson Study Group (2003) Arch. Neurol. 60(12), 1721-1728.
Pascual (1992) Annals of Neurology 32(5), 703-707.
Pierot (1988) J. Neurological Sciences 86, 291-306.
Tuite (2003) Expert Opin. Investig. Drugs 12(8), 1335-1352.
Vila (2003) Nat. Rev. Neurosci 4(5), 365.
Wenning et al. (2004) Lancet Neurology 3, 93-103.
Becker, et al. ( (2002) “Early diagnosis of Parkinson's disease.” J Neurol 249(Suppl 3):III/40-III/48.
Gerlach, et al. (2003) “Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease.” Neurotoxicity Research 5(1):43-51.
Guttman, et al. (2003) Current concepts in the diagnosis and management on Parkinson's disease. CMAJ, 168(3):293-301.
Hughes, et al. (1992) “Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.” Journal of Neurology, Neurosurgery, and Psychiatry 55:181-184.
Kihara, et al. (2002) “Protective effect of dopamine D2 agonists in cortical neurons via the phosphatidylinositol 3 kinase casade.” J. Neurosci. Res. 70:274-282.
Martinez-Martin, et al. (1994) “Unified Parkinson's disease rating scale characteristics and structure.” Movement Disorders 9(1):76-83.
McKay, et al. (2008) “Will stem cell biology generate new therapies for Parkinson's disease?” Neuron 58:659-661.
Nair, et al. (2003) “Activation of phosphoinositide 3-kinase by D2receptor prevents apoptosis in dopaminergic cell lines.” Biochem. J. 373:25-32.
Oertel, et al. (2003) “New aspects in the treatment of Parkinson's disease.” Akt Neurol 30(Suppl 2):S263-265.
Oertel, et al. (2003) “New aspects in the treatment of Parkinson's disease.” Akt Neurol 30(Suppl 2):S263-265 (English Translation).
R & D Focus Drugs News, Aug. 20, 2001, “Drug delivery system, transdermal rotigotine Schwartz clinical data (treatment of Parkinson's disease.” IMS World Pulications Ltd. ISSN:1350-1135.
Schapira (2002) “Neuroprotection and dopamine agonists.” Neurology 58(Suppl 1):S9-S18.
Scheller, et al. (2007) “Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease.” Experimental Neurology 203:415-422.
Scheller, et al. (2008) “Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson's disease.” Neuroscience Letters 432:30-34.
Sherman (2001) “Augmentation strategy aids treatment-resistant depression. (Dopamine Agonist).(pramipexole for mental depression).” Clinical Psychiatry News p. 1-2.
Shoulson, et al. (2003) “A controlled trial of rotigotine monotherapy in early Parkinson's disease.”
Harness & Dickey & Pierce P.L.C.
Javanmard Sahar
Padmanabhan Sreeni
UCB Pharma GmbH
LandOfFree
Use of rotigotine for treating and preventing Parkinson's... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of rotigotine for treating and preventing Parkinson's..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of rotigotine for treating and preventing Parkinson's... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2730569